医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
4期
16-17
,共2页
步长稳心颗粒%心房颤动%胺碘酮
步長穩心顆粒%心房顫動%胺碘酮
보장은심과립%심방전동%알전동
Step metacentric particles%Atrial fibrillation%Amiodarone
目的：观察步长稳心颗粒与胺碘酮联合应用对老年患者持续性心房颤动（房颤）的临床疗效。方法：选择老年持续性房颤患者62例，随机分为两组，对照组30例应用胺碘酮口服治疗，治疗组32例应用胺碘酮＋步长稳心颗粒口服治疗，观察两组的复律成功率及治疗后12个月的窦性心律维持率，并测量复律成功即刻和复律后12个月的左心房直径。结果：治疗组复律成功率显著高于对照组(67.7%；41.4%)(P＜0.05），治疗9个月后治疗组窦性心律维持率显著高于对照组，治疗组于治疗后12个月左心房直径（cm）显著小于对照组（3.53±0.17；3.72±0.25）（P＜0.05）。结论：步长稳心颗粒能有效改善胺碘酮对老年患者持续性房颤的转复律及窦性心律维持率，并能抑制左心房的扩大。
目的：觀察步長穩心顆粒與胺碘酮聯閤應用對老年患者持續性心房顫動（房顫）的臨床療效。方法：選擇老年持續性房顫患者62例，隨機分為兩組，對照組30例應用胺碘酮口服治療，治療組32例應用胺碘酮＋步長穩心顆粒口服治療，觀察兩組的複律成功率及治療後12箇月的竇性心律維持率，併測量複律成功即刻和複律後12箇月的左心房直徑。結果：治療組複律成功率顯著高于對照組(67.7%；41.4%)(P＜0.05），治療9箇月後治療組竇性心律維持率顯著高于對照組，治療組于治療後12箇月左心房直徑（cm）顯著小于對照組（3.53±0.17；3.72±0.25）（P＜0.05）。結論：步長穩心顆粒能有效改善胺碘酮對老年患者持續性房顫的轉複律及竇性心律維持率，併能抑製左心房的擴大。
목적：관찰보장은심과립여알전동연합응용대노년환자지속성심방전동（방전）적림상료효。방법：선택노년지속성방전환자62례，수궤분위량조，대조조30례응용알전동구복치료，치료조32례응용알전동＋보장은심과립구복치료，관찰량조적복률성공솔급치료후12개월적두성심률유지솔，병측량복률성공즉각화복률후12개월적좌심방직경。결과：치료조복률성공솔현저고우대조조(67.7%；41.4%)(P＜0.05），치료9개월후치료조두성심률유지솔현저고우대조조，치료조우치료후12개월좌심방직경（cm）현저소우대조조（3.53±0.17；3.72±0.25）（P＜0.05）。결론：보장은심과립능유효개선알전동대노년환자지속성방전적전복률급두성심률유지솔，병능억제좌심방적확대。
ObjectiveObservation metacentric particles with amiodarone combined application of elderly patients with persistent atrial fibrillation (af) clinical curative effect.Method choose 62 cases of elderly patients with persistent af were randomly divided into two groups, control group 30 cases of application of amiodarone oral treatment, treatment group and 32 cases of application of amiodarone + metacentre grain oral treatment.Resultsthe treatment group cardioerter success rate is significantly higher than control group (67.7%, 41.4%) (P < 0.05), treatment group after treatment for 12 months left atrium diameter (Cm) was significantly less than the control group (3.53 ± 3.53± 0.17; 3.53) (P<0.05).Conclusion metacentric particles can effectively improve amiodarone turn answer law of elderly patients with persistent atrial fibrillation and sinus rhythm maintenance ratio, and can restrain the left atrial enlargement.
